CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Founder's Award: Dr. Joseph Pater Excellence in Clinical Trials Research The Founder's Award is presented annually to an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This award honours an Investigator whose excellence in clinical trials research has provided techniques, information or concepts that will direct the future of the oncology research community and the Canadian Cancer Trials Group.
Update: Non-funded invitations will be sent and request an invitation portal opens at the beginning of March.
If you are planning meetings and/or attending the Spring Meeting be sure to read your invitation carefully so you are clear on the the funding support associated with your invitation.
Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171)
CCTG would like to welcome our new Patient Representative, Catherine Wreford who will be supporting the Brain Cancer Disease Site Committee. Catherine is a professional dancer and actress who was born and raised in Winnipeg, Manitoba, Canada. In 2013, a little over a month after giving birth to her second child, Catherine was diagnosed with incurable anaplastic astrocytoma (a malignant brain tumour).
Please note that in the lead up to Family Day, CCTG Central Office will have limited coverage of critical activities only on Friday February 17th and will be closed Monday
